Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512982-15-00

Acronym

D0817C00098

Enrollment

Registered

2024-08-13

Start date

2021-06-28

Completion date

Unknown

Last updated

2025-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BRCA Mutated Ovarian Cancer Patients, endometrium cancer, Epithelian ovarian cancer, Metastatic Breast Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, Platinum Sensitive Relapsed Ovarian Cancer, prostate cancer

Brief summary

SAEs and AESIs reported until 30 days after the last dose of study drug.

Interventions

DRUGLynparza 150 mg film-coated tablets

DRUGLynparza 100 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
SAEs and AESIs reported until 30 days after the last dose of study drug.	—

Countries

Belgium, Bulgaria, Czechia, France, Germany, Hungary, Italy, Poland, Portugal, Slovenia, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026